This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

7 Stocks Hitting New 52-Week Highs

Stocks in this article: SBUXAMGNWMTPETMPGNXELNHSTM

Amgen

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Amgen (AMGN) is an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. This stock is trading up 1.7% to $62.41 in recent trading after hitting a 52-week high of $62.50 earlier in the day.

Today's Range: $61.00-$62.50

52-Week Range: $47.66-$61.53

Volume: 4.7 million

Three-Month Average Volume: 8.3 million

Amgen has a market cap of $54.71 billion and an enterprise value of $50.20 billion. This stock trades at a trailing price-to-earnings of 15.45 and a forward price-to-earnings of 10.75. Its estimated growth rate for this year is 2.1%, and for next year it's pegged at 9.2%. The current short interest as a percentage of the float for Amgen is very low at 2.5%.

From a technical standpoint, AMGN broke out recently above some near-term overhead resistance of $59.43 on solid volume.

Market players should now watch for AMGN to re-test its next significant overhead resistance level at $65 in the coming days or weeks, as long as the stock continues to trend above $59.43. Traders should look for long biased trades with a target of $65, as long as the volume on the up days remains near or above 8.3 million shares.

Amgen is one of the highest-yielding drug stocks.

3 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs